Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

[Exploration of novel therapeutic molecules for urothelial cancer based on the molecular subtypes and metabolomics]

Original in Japanese: Exploration of novel therapeutic molecules for urothelial cancer based on the molecular subtypes and metabolomics

Funder: Japan Society for the Promotion of Science

Funding period
JPY 4.3 M
USD 39 K
Funding amount
Abstract
[Up to now, sequential treatment with anticancer chemotherapy has been performed for advanced or metastatic urothelial cancer, but recently, the efficacy of cancer immunotherapy (IO) for urothelial cancer has been revealed. On the other hand, urothelial carcinoma is classified into several molecular subtypes, and it is suggested that these are closely related to the responsiveness to chemotherapy and IO therapy. In this study, we clarify the characteristics of metabolome analysis of urothelial cancer from the intracellular dynamics of metabolites in each molecular subtype, and identify new biomarkers and therapeutic target molecules that predict therapeutic response. Is intended to be explored.]
Original in Japanese
これまで進行性または転移性尿路上皮癌に対して抗癌化学療法の逐次療法が行われてきたが最近、癌免疫(I-O)療法の尿路上皮癌への有効性が明らかにされた。一方、尿路上皮癌いくつかの分子サブタイプに分類され、これらと化学療法やI-O療法への反応性の間には密接な関連があることが示唆されている。本研究では、尿路上皮癌のメタボローム解析により、各分子サブタイプにおける代謝物の細胞内ダイナミクスの違いからそれぞれの特徴を明らかにすると共に、治療反応性を予測する新たなバイオマーカーや治療標的分子を探索しようとするものである。
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science